Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Status:
Recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
This Phase 3 trial is an open-label, randomized study with single-agent Balstilimab (BAL) or
Investigator Choice (IC) chemotherapy (single-agent gemcitabine, irinotecan, pemetrexed,
vinorelbine, or topotecan) in patients with recurrent, persistent, or metastatic cervical
cancer who have progressed after receiving platinum based chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Agenus Inc.
Collaborator:
European Network of Gynaecological Oncological Trial Groups (ENGOT)